These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 37455237)
1. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis. Gilchrist FJ; Bui S; Gartner S; McColley SA; Tiddens H; Ruiz G; Stehling F; Alani M; Gurtovaya O; Bresnik M; Watkins TR; Frankovic B; Skov M; J Cyst Fibros; 2024 Jan; 23(1):80-86. PubMed ID: 37455237 [TBL] [Abstract][Full Text] [Related]
2. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109 [TBL] [Abstract][Full Text] [Related]
3. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM; J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195 [TBL] [Abstract][Full Text] [Related]
5. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Langton Hewer SC; Smith S; Rowbotham NJ; Yule A; Smyth AR Cochrane Database Syst Rev; 2023 Jun; 6(6):CD004197. PubMed ID: 37268599 [TBL] [Abstract][Full Text] [Related]
7. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078 [TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL; Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081 [TBL] [Abstract][Full Text] [Related]